Scarica l'app Stockscreener
203.10
1.16%
-2.39
Pre-mercato:
204.50
1.40
+0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$205.49
Aprire:
$205.68
Volume 24 ore:
299.54K
Relative Volume:
0.36
Capitalizzazione di mercato:
$10.64B
Reddito:
$708.24M
Utile/perdita netta:
$-188.30M
Rapporto P/E:
-54.32
EPS:
-3.7392
Flusso di cassa netto:
$-70.99M
1 W Prestazione:
-0.48%
1M Prestazione:
-2.25%
6M Prestazione:
+29.43%
1 anno Prestazione:
+72.87%
Intervallo 1D:
$202.52
$207.01
Intervallo di 1 settimana:
$201.94
$216.47
Portata 52W:
$115.31
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
203.10 | 11.56B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
About Axsome Therapeutics, Inc. rStock - Coinbase
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2036 – DelveInsight | Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Lab, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’ - Stocktwits
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 7%Should You Buy? - MarketBeat
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Axsome Therapeutics, Inc. $AXSM Shares Bought by California State Teachers Retirement System - MarketBeat
Axsome at cantor healthcare conference: auvelity growth accelerates By Investing.com - Investing.com South Africa
Transcript : Axsome Therapeutics, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02 - marketscreener.com
AXSM: AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth - TradingView
Axsome at cantor healthcare conference: auvelity growth accelerates - investing.com
AXSM: AUVELITY's rapid growth and robust CNS pipeline position the company for significant expansion - TradingView
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Axsome Therapeutics Inc (19X) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics (AXSM) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Axsome Therapeutics at Wells Fargo conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics Inc (19X) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Axsome reports strong growth for its CNS drugs ... - Pluang
Axsome Therapeutics Inc (19X) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials - TradingView
Transcript : Axsome Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Axsome Therapeutics at Wells Fargo conference: growth broadens - investing.com
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily
Hsbc Holdings PLC Sells 12,653 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Axsome Therapeutics (NASDAQ:AXSM) Entering A Turning Point? - Kalkine Media
33,554 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Readystate Asset Management LP - MarketBeat
Axsome Therapeutics (AXSM) Investor Outlook: Unveiling a 38% Upside Potential Amidst Rapid Growth in CNS Therapies - DirectorsTalk Interviews
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Seven Fleet Capital Management LP Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,293 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Public Employees Retirement System of Ohio - MarketBeat
Corient Private Wealth LP Makes New $1.26 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $2.08m of company stock - Investing.com Nigeria
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Axsome Therapeutics (AXSM) Institutional Ownership 2026 - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $2,086,500.00 in Stock - MarketBeat
Axsome Therapeutics (AXSM) COO sells 10,000 shares in pre-set trading plan - Stock Titan
Planned $2.1M Axsome Therapeutics (AXSM) stock sale set under pre-arranged trading plan - Stock Titan
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256 - moomoo.com
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Legal & General Group Plc Makes New $8.10 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Van ECK Associates Corp Has $7.17 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
20,091 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Alyeska Investment Group L.P. - MarketBeat
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation - Yahoo Finance
Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says - marketscreener.com
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
0.14%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):